Exact Sciences EXAS

EXAS

$104.91 +0.99 (+0.95%)

At close: Mar 20, 2026 · 4:00 PM EDT

Key Stats

Add ratio to table…

About

Exact Sciences Corporation is a leading provider of cancer screening and diagnostic tests that aim to detect cancer earlier and guide treatment decisions. The company develops and commercializes non invasive stool based DNA tests for colorectal cancer and blood based multi cancer early detection tests. Its portfolio also includes precision oncology genomic tests that help physicians tailor therapy after a cancer diagnosis. In 2025 Exact Sciences delivered more than 5.5 million test results to patients reflecting broad adoption of its screening and diagnostic offerings. The company launched Cologuard Plus an improved stool DNA test, Oncodetect a molecular residual disease test, and Cancerguard a multi cancer early detection blood test. Exact Sciences operates primarily in the United States while expanding the international reach of its Oncotype DX franchise.

Exact Sciences generates revenue mainly from the sale of its diagnostic tests to patients, health care providers, hospitals, and laboratories. Revenue also comes from licensing agreements and partnerships, such as the collaboration with Quest Diagnostics for specimen collection, and the exclusive license with Freenome for blood based colorectal cancer screening technology. In 2025 the company reported revenue growth of 18 percent while decreasing operating expenses as a percentage of revenue. Cash provided by operating activities was $491.4 million, an increase of $280.9 million compared with the prior year. The average revenue per Cologuard Plus test is approximately $592 and with nearly 110 million Americans aged 45 to 85 at average risk for colorectal cancer the three year screening interval represents a potential market of about $22 billion annually. Reimbursement from Medicare, commercial payers, and government health plans supports a significant share of sales. Medicare Part B covers Cologuard and Cologuard Plus once every three years for beneficiaries who are age 45 to 85 asymptomatic and at average risk for colorectal cancer. The company’s precision oncology tests including Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncodetect, and Riskguard receive coverage under the Molecular Diagnostics Services Program and other payer policies.

Exact Sciences holds a strong position in the cancer diagnostics industry through its FDA approved tests, broad reimbursement coverage, and proprietary biomarker algorithms. Its Cologuard test was the first FDA approved stool DNA based colorectal cancer screening test and maintains sensitivity of 92 percent and specificity of 87 percent. Cologuard Plus offers improved sensitivity of 95 percent and specificity of 91 percent. The Cancerguard test launched in September 2025 as a self pay laboratory developed test demonstrates sensitivity of 68 percent across six of the deadliest cancers and overall sensitivity of 64 percent across a broad range of cancers excluding breast and prostate with a specificity of 97.4 percent. The Oncodetect MRD test received Medicare reimbursement effective April 2025 for serial use in patients with stage II III and resectable stage IV colorectal cancer showing sensitivity of 78 percent post surgical and 91 percent during surveillance with specificities of 80 percent and 94 percent. The Oncotype DX suite is recognized as standard of care in major breast cancer treatment guidelines and is reimbursed in numerous international markets. Competitors include Guardant Health, GRAIL, Freenome, Natera, Myriad Genetics, Ambry Genetics, LabCorp, and Quest Diagnostics. Exact Sciences differentiates itself through its focus on early detection, its strong pipeline of MRD and MCED tests, and its extensive adherence and patient support programs that help increase test completion rates.

The company serves a broad customer base that includes individual patients seeking cancer screening or diagnostic information, physicians, oncologists, surgeons, hospitals, health systems, clinical laboratories, and payers. Its tests are ordered by primary care providers, gastroenterologists, oncologists, and other specialists. Exact Sciences works with national laboratory service providers such as Quest Diagnostics to expand patient access to its blood based tests including Cancerguard and Oncodetect. Reimbursement relationships with Medicare, Medicaid, and private insurers are critical to the company's commercial success. Internationally the Oncotype DX tests are available in approximately 120 countries outside the United States while the Cologuard, Cancerguard, and Oncodetect tests are not currently offered abroad although the company is exploring opportunities to make these tests available in additional markets.

Investment Thesis

▲ Bull case

Exact Sciences’ Oncotype DX Breast Recurrence Score test has now been used by over two million patients worldwide, underscoring deep clinician and patient trust in a product that has become the standard‑of‑care for early‑stage HR+, HER2‑ breast cancer. This milestone reflects more than two decades of clinical validation and positions the test as a durable moat that continues to drive recurring revenue streams through repeat testing and guideline endorsement. The test’s dual prognostic and predictive capability enables physicians to spare an estimated 1.6 million patients from unnecessary chemotherapy, translating into significant cost savings for the healthcare system and reinforcing value‑based adoption. As guideline committees maintain Category 1A recommendations and international uptake expands into over 100 countries, the test’s penetration remains a reliable growth engine that the market may be underestimating given its entrenched role in precision oncology.
The recent passage of federal legislation creating a Medicare coverage pathway for multi‑cancer early detection (MCED) tests removes a major reimbursement hurdle for Exact Sciences’ Cancerguard® platform. By establishing a clear framework that ties FDA approval to CMS implementation, the legislation paves the way for broad adoption among the Medicare population, which accounts for a substantial share of cancer screenings in the United States. Early modeling suggests that adding Cancerguard to standard‑of‑care screening could cut stage‑IV cancer diagnoses by nearly half, creating a compelling health‑economic narrative that supports premium pricing and rapid uptake. This policy tailwind is likely to accelerate commercialization timelines and expand the addressable market beyond the current colorectal cancer focus, offering a multi‑year growth catalyst that is not yet fully reflected in consensus estimates.
Exact Sciences’ Oncodetect® MRD test demonstrated strong prognostic power in early triple‑negative breast cancer within the NSABP B‑59 substudy, showing that postoperative ctDNA positivity predicts distant recurrence with high sensitivity. This data set, one of the largest TNBC MRD cohorts analyzed to date, provides a robust foundation for pursuing FDA clearance and Medicare reimbursement in a high‑need oncology segment where few non‑invasive monitoring tools exist. Successful commercialization of Oncodetect in breast cancer could unlock a new precision‑oncology revenue stream complementary to the established Oncotype DX franchise, diversifying the company’s product mix and reducing reliance on any single test. The ability to guide adjuvant therapy decisions based on molecular residual disease aligns with the industry shift toward personalized, risk‑adapted treatment, positioning Exact Sciences at the forefront of this evolving standard of care.
The launch of Cologuard Plus® in the Q1 FY25, featuring novel biomarkers and improved laboratory processes, has already shown a potential false‑positive reduction of nearly 40% compared with the original Cologuard test. This enhancement directly addresses a key pain point for providers and payers—unnecessary follow‑up colonoscopies—thereby improving the test’s cost‑effectiveness and strengthening its value proposition in value‑based care arrangements. With Medicare coverage and guideline inclusion secured at launch, Cologuard Plus is poised to capture additional market share from both existing Cologuard users and competing stool‑based or blood‑based CRC screening options. The incremental uptake of this upgraded test can drive higher average selling prices and improve gross margins, a factor that analysts may be overlooking when modeling the company’s core screening business.
The overwhelming stockholder approval (over 99% of votes) for the proposed acquisition by Abbott signals strong confidence in the strategic rationale and financial terms of the deal, which offers shareholders an immediate cash consideration of $105 per share. While the transaction is pending regulatory clearance, the high level of support reduces the risk of a deal break‑up and suggests that investors view the combined entity as capable of leveraging Abbott’s global scale, distribution network, and resources to accelerate Exact Sciences’ pipeline programs. The integration could provide access to Abbott’s extensive commercial infrastructure in emerging markets, facilitating faster geographic expansion of tests like Cancerguard and Oncodetect beyond the United States. This potential for accelerated international rollout represents a latent upside that may not be fully priced into the current share price awaiting closure.

Exact Sciences’ Oncotype DX Breast Recurrence Score test has now been used by over two million patients worldwide, underscoring deep clinician and patient trust in a product that has become the standard‑of‑care for early‑stage HR+, HER2‑ breast cancer. This milestone reflects more than two decades of clinical validation and positions the test as a durable moat that continues to drive recurring revenue streams through repeat testing and guideline endorsement. The test’s dual prognostic and predictive capability enables physicians to spare an estimated 1.6 million patients from unnecessary chemotherapy, translating into significant cost savings for the healthcare system and reinforcing value‑based adoption. As guideline committees maintain Category 1A recommendations and international uptake expands into over 100 countries, the test’s penetration remains a reliable growth engine that the market may be underestimating given its entrenched role in precision oncology.
The recent passage of federal legislation creating a Medicare coverage pathway for multi‑cancer early detection (MCED) tests removes a major reimbursement hurdle for Exact Sciences’ Cancerguard® platform. By establishing a clear framework that ties FDA approval to CMS implementation, the legislation paves the way for broad adoption among the Medicare population, which accounts for a substantial share of cancer screenings in the United States. Early modeling suggests that adding Cancerguard to standard‑of‑care screening could cut stage‑IV cancer diagnoses by nearly half, creating a compelling health‑economic narrative that supports premium pricing and rapid uptake. This policy tailwind is likely to accelerate commercialization timelines and expand the addressable market beyond the current colorectal cancer focus, offering a multi‑year growth catalyst that is not yet fully reflected in consensus estimates.
Exact Sciences’ Oncodetect® MRD test demonstrated strong prognostic power in early triple‑negative breast cancer within the NSABP B‑59 substudy, showing that postoperative ctDNA positivity predicts distant recurrence with high sensitivity. This data set, one of the largest TNBC MRD cohorts analyzed to date, provides a robust foundation for pursuing FDA clearance and Medicare reimbursement in a high‑need oncology segment where few non‑invasive monitoring tools exist. Successful commercialization of Oncodetect in breast cancer could unlock a new precision‑oncology revenue stream complementary to the established Oncotype DX franchise, diversifying the company’s product mix and reducing reliance on any single test. The ability to guide adjuvant therapy decisions based on molecular residual disease aligns with the industry shift toward personalized, risk‑adapted treatment, positioning Exact Sciences at the forefront of this evolving standard of care.
The launch of Cologuard Plus® in the Q1 FY25, featuring novel biomarkers and improved laboratory processes, has already shown a potential false‑positive reduction of nearly 40% compared with the original Cologuard test. This enhancement directly addresses a key pain point for providers and payers—unnecessary follow‑up colonoscopies—thereby improving the test’s cost‑effectiveness and strengthening its value proposition in value‑based care arrangements. With Medicare coverage and guideline inclusion secured at launch, Cologuard Plus is poised to capture additional market share from both existing Cologuard users and competing stool‑based or blood‑based CRC screening options. The incremental uptake of this upgraded test can drive higher average selling prices and improve gross margins, a factor that analysts may be overlooking when modeling the company’s core screening business.
The overwhelming stockholder approval (over 99% of votes) for the proposed acquisition by Abbott signals strong confidence in the strategic rationale and financial terms of the deal, which offers shareholders an immediate cash consideration of $105 per share. While the transaction is pending regulatory clearance, the high level of support reduces the risk of a deal break‑up and suggests that investors view the combined entity as capable of leveraging Abbott’s global scale, distribution network, and resources to accelerate Exact Sciences’ pipeline programs. The integration could provide access to Abbott’s extensive commercial infrastructure in emerging markets, facilitating faster geographic expansion of tests like Cancerguard and Oncodetect beyond the United States. This potential for accelerated international rollout represents a latent upside that may not be fully priced into the current share price awaiting closure.

▼ Bear case

The pending acquisition by Abbott introduces significant execution risk that could dampen upside potential for shareholders if the transaction fails to close or is delayed beyond the anticipated Q2 FY26 timeline. Regulatory antitrust reviews, particularly given the combined market power in diagnostics, could result in divestitures, conditions, or even a blockage of the deal, leaving Exact Sciences to operate as an independent entity while bearing the costs of merger‑related expenses already incurred. Even if the deal closes, integration challenges—such as aligning disparate commercial cultures, consolidating overlapping sales forces, and harmonizing IT systems—could distract management from core business initiatives and slow the rollout of new tests like Cancerguard and Oncodetect. These risks are not fully reflected in the current share price, which assumes a smooth transition and immediate synergies.
Exact Sciences faces intensifying competition in the colorectal cancer screening arena, most notably from Geneoscopy’s ColoSense test, which recently prevailed in a PTAB invalidation of Exact Sciences’ key patents covering stool‑based DNA marker detection. The loss of patent protection opens the door for increased generic or alternative noninvasive CRC screening options that could erode Cologuard’s market share, especially if competitors achieve comparable sensitivity at lower cost. Additionally, large diagnostics firms and emerging biotech entrants are investing heavily in blood‑based CRC screening and multi‑cancer early detection platforms, which could fragment the market and exert pricing pressure on Exact Sciences’ flagship offerings. The company’s reliance on a single dominant test for a substantial portion of revenue makes it vulnerable to shifts in clinician preference or reimbursement changes favoring rival technologies.
Reimbursement uncertainty remains a material headwind, particularly for newer diagnostic modalities such as the Cancerguard® MCED test and Oncodetect® MRD assay, which have not yet secured FDA clearance or widespread Medicare coverage. While recent federal legislation creates a pathway for MCED reimbursement, the actual implementation timeline, coverage criteria, and payment rates are still unknown and could be less favorable than anticipated, limiting adoption rates. Moreover, any changes to Medicare fee schedules, adjustments to the Clinical Laboratory Fee Schedule, or shifts in private payer policies toward bundled payments could negatively impact the profitability of high‑margin tests. The company’s historical dependence on favorable reimbursement for Cologuard underscores the sensitivity of its revenue model to policy shifts, a risk that may be underestimated by investors focused solely on topline growth.
The company’s elevated operating expenses, particularly in research and development and sales and marketing, have risen sharply, with R&D spending increasing nearly 100% year‑over‑year in the Q4 FY25 and sales and marketing expenses growing at a double‑digit pace. While these investments are intended to fuel future growth, they have contributed to GAAP losses and could pressure profitability if the anticipated revenue uplift from new products fails to materialize on schedule. The adjusted EBITDA margin, although stable at around 12%, relies heavily on excluding significant non‑cash and merger‑related charges, suggesting that the underlying GAAP profitability remains fragile. If the market reevaluates the quality of earnings and places greater weight on GAAP results, the stock could face downward pressure despite robust non‑GAAP metrics.
Macroeconomic factors, including potential slowdowns in healthcare spending, inflationary pressures on labor and supply chain costs, and fluctuations in foreign exchange rates, could adversely affect Exact Sciences’ international expansion plans and margin profile. Although the company reports limited foreign currency impact on core revenue, a substantial portion of its Precision Oncology business derives from ex‑U.S. sales that remain vulnerable to currency volatility. Additionally, a broader economic downturn could lead hospitals and health systems to defer capital expenditures on diagnostic testing or prioritize lower‑cost alternatives, slowing the uptake of higher‑priced tests like Oncotype DX and Cologuard Plus. These external headwinds are not fully captured in the company’s internal guidance and could constrict growth expectations.

The pending acquisition by Abbott introduces significant execution risk that could dampen upside potential for shareholders if the transaction fails to close or is delayed beyond the anticipated Q2 FY26 timeline. Regulatory antitrust reviews, particularly given the combined market power in diagnostics, could result in divestitures, conditions, or even a blockage of the deal, leaving Exact Sciences to operate as an independent entity while bearing the costs of merger‑related expenses already incurred. Even if the deal closes, integration challenges—such as aligning disparate commercial cultures, consolidating overlapping sales forces, and harmonizing IT systems—could distract management from core business initiatives and slow the rollout of new tests like Cancerguard and Oncodetect. These risks are not fully reflected in the current share price, which assumes a smooth transition and immediate synergies.
Exact Sciences faces intensifying competition in the colorectal cancer screening arena, most notably from Geneoscopy’s ColoSense test, which recently prevailed in a PTAB invalidation of Exact Sciences’ key patents covering stool‑based DNA marker detection. The loss of patent protection opens the door for increased generic or alternative noninvasive CRC screening options that could erode Cologuard’s market share, especially if competitors achieve comparable sensitivity at lower cost. Additionally, large diagnostics firms and emerging biotech entrants are investing heavily in blood‑based CRC screening and multi‑cancer early detection platforms, which could fragment the market and exert pricing pressure on Exact Sciences’ flagship offerings. The company’s reliance on a single dominant test for a substantial portion of revenue makes it vulnerable to shifts in clinician preference or reimbursement changes favoring rival technologies.
Reimbursement uncertainty remains a material headwind, particularly for newer diagnostic modalities such as the Cancerguard® MCED test and Oncodetect® MRD assay, which have not yet secured FDA clearance or widespread Medicare coverage. While recent federal legislation creates a pathway for MCED reimbursement, the actual implementation timeline, coverage criteria, and payment rates are still unknown and could be less favorable than anticipated, limiting adoption rates. Moreover, any changes to Medicare fee schedules, adjustments to the Clinical Laboratory Fee Schedule, or shifts in private payer policies toward bundled payments could negatively impact the profitability of high‑margin tests. The company’s historical dependence on favorable reimbursement for Cologuard underscores the sensitivity of its revenue model to policy shifts, a risk that may be underestimated by investors focused solely on topline growth.
The company’s elevated operating expenses, particularly in research and development and sales and marketing, have risen sharply, with R&D spending increasing nearly 100% year‑over‑year in the Q4 FY25 and sales and marketing expenses growing at a double‑digit pace. While these investments are intended to fuel future growth, they have contributed to GAAP losses and could pressure profitability if the anticipated revenue uplift from new products fails to materialize on schedule. The adjusted EBITDA margin, although stable at around 12%, relies heavily on excluding significant non‑cash and merger‑related charges, suggesting that the underlying GAAP profitability remains fragile. If the market reevaluates the quality of earnings and places greater weight on GAAP results, the stock could face downward pressure despite robust non‑GAAP metrics.
Macroeconomic factors, including potential slowdowns in healthcare spending, inflationary pressures on labor and supply chain costs, and fluctuations in foreign exchange rates, could adversely affect Exact Sciences’ international expansion plans and margin profile. Although the company reports limited foreign currency impact on core revenue, a substantial portion of its Precision Oncology business derives from ex‑U.S. sales that remain vulnerable to currency volatility. Additionally, a broader economic downturn could lead hospitals and health systems to defer capital expenditures on diagnostic testing or prioritize lower‑cost alternatives, slowing the uptake of higher‑priced tests like Oncotype DX and Cologuard Plus. These external headwinds are not fully captured in the company’s internal guidance and could constrict growth expectations.

Peer group

Peer Comparison

Companies in the Diagnostic Labs

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	NTRA	Natera, Inc.	primary	47.44 Bn	-246.72	17.52	0.16 Bn
2	LH	Labcorp Holdings Inc.	primary	26.30 Bn	26.21	1.83	5.86 Bn
3	DGX	Quest Diagnostics Inc	primary	26.21 Bn	24.18	2.27	5.65 Bn
4	GH	Guardant Health, Inc.	primary	21.64 Bn	-47.72	18.29	-
5	TEM	Tempus AI, Inc.	primary	11.04 Bn	-44.44	7.71	-
6	CAI	Caris Life Sciences, Inc.	primary	6.82 Bn	64.87	6.89	0.39 Bn
7	SHC	Sotera Health Co	primary	5.24 Bn	32.03	4.31	2.15 Bn
8	BLLN	BillionToOne, Inc.	primary	4.63 Bn	154.14	11.66	0.09 Bn

Exact Sciences EXAS

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password